Genito Urinary System and Sex Hormones

Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune's Palforzia, expanding its broader spectrum of solutions for children living with food allergies. Palforzia is the first therapy approved to reduce the frequency and severity of allergic reactions associated with Peanut allergy,  including anaphylaxis, in children aged 4 through 17.  The drug can be used in conjunction with a peanut-avoidant diet....